Johnson & Johnson

Oncology

Henar Hevia & Carolyn Sousa interview with Nicole Raleigh

ESMO 2024 - Henar Hevia & Carolyn Sousa

ESMO 2024 was chock full of oncological data, diverse presentations providing hope across the cancer spectrum from breast and lung to unmet needs in colorectal and bladder.

News

Sanofi's Sarclisa gets one up on rival Darzalex in myeloma

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight.

News

J&J tries to push talc bankruptcy over the line once again

Johnson & Johnson's long-running effort to put litigation claiming its talc products caused cancer has continued with a third attempt to place a subsidiary company into bankruptcy.

News

J&J nets another key approval for blockbuster hope Rybrevant

Johnson & Johnson's target of $5 billion in sales for its EGFRxMET bispecific antibody Rybrevant has moved a step closer, after a new FDA approval in non-small cell lung cancer (NSCLC).

News

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

Johnson & Johnson is planning a phase 3 programme for Rybrevant in colorectal cancer as a follow-up to its first indication in non-small cell lung cancer (NSCLC), after reporting encour

News

J&J sweetens controversial talc settlement deal

In a bid to put litigation over the safety of its talc products into the rearview mirror, Johnson & Johnson has added another $1.1 billion to its settlement offer, according to media re

ESMO 2024 - Henar Hevia & Carolyn Sousa

Sanofi's Sarclisa gets one up on rival Darzalex in myeloma

J&J tries to push talc bankruptcy over the line once again

J&J nets another key approval for blockbuster hope Rybrevant

ESMO: J&J cues up phase 3 for Rybrevant in colorectal cancer

J&J sweetens controversial talc settlement deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Johnson & Johnson

Editor's Picks